The third party South Korean health insurance claims data used in this study is available in the South Korean Health Insurance Review and Assessment service Healthcare Bigdata Hub website (<http://opendata.hira.or.kr/op/opc/selectPatDataAplInfoView.do>) for researchers who make a payment of 300,000 KRW for each year of data. The authors confirm that they had no special access privileges to the data and paid the data access fee. The US Medicare data is available to the public at <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2014.html>.

Introduction {#sec006}
============

The geriatric population is at risk for drug related adverse events as they tend to have acute illnesses and are exposed to several medications \[[@pone.0191376.ref001], [@pone.0191376.ref002]\]. A previous study revealed that around half of older populations take five or more medications \[[@pone.0191376.ref002]\]. This population also has physiological changes attributed to aging and this may influence the pharmacokinetics and pharmacodynamics of drugs increasing the risk of drug therapy \[[@pone.0191376.ref003], [@pone.0191376.ref004]\]. There were studies showing that inappropriate medication prescribing was common in the geriatric population with rates up to 40.0% \[[@pone.0191376.ref003]\]. Inappropriate prescribing are those practices where the risk of adverse drug events (ADEs) from prescribing the medication is higher than the benefit \[[@pone.0191376.ref003]\].

This type of inappropriate prescribing is known to be associated with ADEs and hospitalization and around 12% of elderly hospital admissions are caused by adverse drug reactions \[[@pone.0191376.ref005]\]. ADEs are a significant problem as these increase the morbidity and mortality of patients, and in Western countries, make up 3--5% of hospital admissions and around 10% of hospitalization costs \[[@pone.0191376.ref006]\].

Beers et al. made criteria with drugs considered inappropriate in the elderly in 1991 \[[@pone.0191376.ref007]\]. This criteria lists drugs or drug classes to avoid in patients aged 65 years or more due to risk of ADEs including anticholinergic effects, physical dependence, cognitive impairment as well as those that have drug-disease interactions that worsen the disease of the geriatric patient \[[@pone.0191376.ref005]\]. The goal of the criteria was to improve geriatric pharmacotherapy through decreasing the exposure of the elderly to potentially inappropriate medications. These medications were seen to be commonly prescribed in hospitals and were known to decrease the health of the elderly \[[@pone.0191376.ref006], [@pone.0191376.ref007]\]. This criteria was updated in year 2003, 2012, and 2015 and is now frequently used as a safety resource in geriatric pharmacotherapy, education, and research \[[@pone.0191376.ref008]\].

The aim of this study was to assess the exposure of South Korean geriatrics to potentially inappropriate medications in the Beers Criteria and their risk of ADEs from the medications. This was performed to measure the extent of ADE risk that South Korean geriatric patients were exposed to and the need of safety measures to prevent the ADEs.

Materials and methods {#sec007}
=====================

Study population {#sec008}
----------------

This was a cross-sectional study including South Korean patients 65 years of age or older. The claims data of this population issued in year 2011 was used to extract the medication use of these patients (claims dataset serial number, HIRA-2011-0133). The dataset used was collected by the Health Insurance Review and Assessment service (HIRA) and includes the health claims data for 3% of the total South Korean population. This population was selected in the dataset using stratified sampling using gender and 5-year age group and was shown to be representative of 95% of the total South Korean population \[[@pone.0191376.ref009], [@pone.0191376.ref010]\]. The total number of patients in this dataset was 1,375,842 and the number of geriatrics 65 years of age or older was 166,822 (12.13%).

Study medications {#sec009}
-----------------

The 2015 Beers Criteria medication (BCM) list was used for this study. BCMs to be avoided in patients 65 years or older were included for analysis regardless of concomitant disease or meds. The reason for this was because the health claims data did not provide sufficient information to extract patients who satisfy when to avoid the BCM considering concomitant disease or drug therapy of the patient. The number of medications in the 2015 BCM list was 115 and among these, the number of medications that were to be avoided in the elderly over 65 years of age regardless of concomitant disease or drug therapy was 82.

Population exposure to study medication {#sec010}
---------------------------------------

The exposure of the South Korean geriatric study patients to each of the 82 BCMs was examined by counting the number of patients who had a claim for each BCM with a prescription duration of more than one day according to the 2011 HIRA claims data. The count of patients on the med was denoted as *N~med~*. For comparison of South Korean geriatric exposure to BCM with that of US geriatrics, the Part D Prescriber National Summary Report, Calendar Year 2014 was downloaded from the Centers for Medicare & Medicaid Services website. This data included the number of Medicare Part D beneficiaries who had claims to medications \[[@pone.0191376.ref011]\]. The total number of Medicare beneficiaries in 2014 was 54,095,565 and this was used to estimate the proportion of US geriatrics aged 65 years or older exposed to BCMs \[[@pone.0191376.ref012]\]. The number of South Koreans on a BCM for one day or less was examined separately to account for ADEs that may have occurred from or short term meds. The number of patients on BCMs for this duration were denoted as *N~med,short~*.

The overall workflow for this study is in [Fig 1](#pone.0191376.g001){ref-type="fig"}.

![Overall workflow of the study.\
*AGS* American Geriatrics Society; *ADE* adverse drug event, *BCM* Beers Criteria medication.](pone.0191376.g001){#pone.0191376.g001}

Population at risk of ADE {#sec011}
-------------------------

A literature search in PubMed was performed to extract the incident rate of adverse drug events (ADEs) from the study meds in Asians and the US population for calculating the number of populations at risk of ADEs in South Korea and US, respectively. The literature sources preferred for analysis were those in English or translated in English, included subjects of age 65 years and older, studied subjects of Asian race (or subjects in the US if obtaining rates for US population), and were a meta-analysis. If there was no literature source for the ADE incident rate exclusively in geriatrics 65 years or over, studies including subjects aged \<65 years as well as those ≥65 years if available were used. In the case were there were no meta-analyses, single studies were included. If there were multiple studies satisfying the above criteria, the more recent study was used to extract the ADE incident rate. The PubMed search term was "study drug AND elderly (or geriatric) AND side effect (or adverse event) AND Asia" for extracting ADE rates in the South Korean population and "study drug AND elderly (or geriatric) AND side effect (or adverse event)" for extracting ADE rates in the US population. Using the number of exposed South Korean geriatrics to each study med and the med-related ADE incident rates extracted from the literature, the number of geriatrics at risk of the BCM related ADE was calculated. The formula for this calculation was $$N_{med–ADE} = N_{med} \times Pr\left( ADE \middle| med \right),$$ where *med* indicates the BCM of our study, *N~med--ADE~* the number of geriatrics at risk of an ADE from a *med*, *N~med~* the number of geriatrics exposed to a *med*, and Pr(*ADE*\|*med*) the incidence rate of ADE from the *med* in geriatrics.

Statistical analysis {#sec012}
--------------------

The Chi-squared test was used to evaluate the difference in frequency of BCMs prescribed in South Korean geriatrics for \>1 day versus ≤1 day or versus the BCM prescription frequency in US geriatrics. The proportions of South Koreans on BCMs \>1 day versus ≤1 day at risk of ADEs grouped by Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) was compared using 2-way ANOVA using the factors prescription duration and MedDRA SOC, with pairwise *t*-test for post hoc analysis. In addition, 2-way ANOVA was used to compare the proportions of South Koreans on BCMs \>1 day and US geriatrics at risk of ADEs again grouped by MedDRA SOC using two factors, the national location of the patients and the SOCs, with pairwise *t*-test for post hoc analysis. The South Korean geriatrics on BCMs for \>1 day were used for ADE risk comparison with US geriatrics due to the data source used for US geriatrics including prescription data of chronic disease Medicare beneficiaries \[[@pone.0191376.ref011], [@pone.0191376.ref013]\]. The mean risk of ADEs grouped by SOCs were compared between South Korean geriatrics on BCMs \>1 day and ≤1 day as well as South Korean geriatrics on BCMs for \>1 day and US geriatrics using the two sample *t*-test. Each of the BCM ADEs were grouped into SOCs using the BioPortal ontology library \[[@pone.0191376.ref014]\]. All statistical tests were carried out with a significance level of *P*\<0.05 using R version 3.3.2 \[[@pone.0191376.ref015]\].

Ethical approval {#sec013}
----------------

The personal identification information of samples in the South Korean HIRA service and the CMS Part D Prescriber National Summary Report, Calendar Year 2014 was removed prior to data download for this study. Therefore, formal consent of the study sample was not required.

Results {#sec014}
=======

Study population {#sec015}
----------------

The demographics of the study population are in [Table 1](#pone.0191376.t001){ref-type="table"}. The number of the target geriatric population who were ≥65 years of age was 166,822. The mean (standard deviation, SD) age of the study population was 73.1 (6.5) years and 98,714 (59.2%) were women. The mean (SD) number of medications prescribed per patient was 30 (20.1). The number of people prescribed at least one prescription for a BCM inappropriate in the elderly of 65 years of age or older regardless of concomitant disease or drug was 128,749 (77.2%). The number of people prescribed two or more of such prescriptions was 107,430 (64.4%) and three or more was 91,427 (54.8%).

10.1371/journal.pone.0191376.t001

###### Demographics of the study population.

![](pone.0191376.t001){#pone.0191376.t001g}

  Variable                                                    Total (n = 166,822)
  ----------------------------------------------------------- ---------------------
  Age, y (mean±SD)                                            73.1±6.5
  Female gender, n (%)                                        98,714 (59.2)
  Medications per person, n (mean±SD)                         30±20.1
  Population prescribed at least X BCM prescriptions, n (%)   
      1                                                       128,749 (77.2)
      2                                                       107,430 (64.4)
      3                                                       91,427 (54.8)

*SD* standard deviation, *BCM* Beers Criteria medication.

Population exposure to study medications {#sec016}
----------------------------------------

The prevalence of South Koreans on BCMs is shown in [Table 2](#pone.0191376.t002){ref-type="table"}. The meds were sorted by prevalence of prescribing BCMs \>1 day in South Korean geriatrics. This prevalence was compared with that of US geriatrics. The most prevalent BCM prescribed in South Korean geriatrics for \>1 day was chlorpheniramine (53.9%), a first-generation antihistamine, followed by the benzodiazepines, diazepam (23.7%), and alprazolam (13.0%). The most prevalent BCM prescribed in South Korean geriatrics for ≤1 day was chlorpheniramine (21.9%), a first-generation antihistamine, followed by a benzodiazepine, diazepam (4.6%), and ketorolac, a nonsteroidal antiinflammatory drug (3.4%). In US geriatrics, alprazolam (4.7%) was most prevalently prescribed, followed by lorazepam (4.0%), and zolpidem (3.9%). Out of the 82 BCMs, 35 were prescribed at least once in South Korean geriatrics for \>1 day and 33 prescribed for ≤1 day while 66 were prescribed in US geriatrics. Comparing prescription rates between the South Korean geriatrics on \>1 day or ≤1 day of BCMs, 31 meds were prescribed at a significantly higher rate in South Korean geriatrics prescribed BCMs \>1 day, 2 meds at a significantly higher rate in geriatrics prescribed BCMs ≤1 day, and 2 meds were unknown as the prescribing frequency was not available for at least one of the population groups. Comparing prescription rates between the two countries, 22 meds were prescribed at a significantly higher rate in South Korean geriatrics prescribed BCMs \>1 day, 35 meds at a significantly higher rate in US geriatrics, and 16 were unknown as the prescribing frequency was not available in the geriatric population of one or either countries.

10.1371/journal.pone.0191376.t002

###### Exposure of South Korean and US geriatrics to Beers Criteria medications not recommended in geriatrics regardless of concomitant disease or drugs.

![](pone.0191376.t002){#pone.0191376.t002g}

  BCM (n = 82)                                                                                                    No. South Korean sample population (%, total sample no. 166,822)   Minimum no. US patients on Medicare Part D on BCM in 2014 (%, total no. 54,095,565)   
  --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------- -----------------
  Chlorpheniramine[^✝^](#t002fn003){ref-type="table-fn"}                                                          89,923 (53.9)                                                      36,474 (21.9)                                                                         NA
  Diazepam[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                          39,467 (23.7)                                                      7,659 (4.6)                                                                           1,077,677 (2.0)
  Alprazolam[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                        21,705 (13.0)                                                      1,605 (1.0)                                                                           2,544,993 (4.7)
  Dimenhydrinate[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                    19,419 (11.6)                                                      1,990 (1.2)                                                                           27 (0.0)
  Hydroxyzine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                       17,719 (10.6)                                                      1,406 (0.8)                                                                           478,644 (0.9)
  Zolpidem[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                          14,278 (8.6)                                                       1,856 (1.1)                                                                           2,134,655 (3.9)
  Orphenadrine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                      11,271 (6.8)                                                       571 (0.3)                                                                             48,876 (0.1)
  Amitriptyline[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                     10,913 (6.5)                                                       551 (0.3)                                                                             805,092 (1.5)
  Methocarbamol[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                     6,747 (4.0)                                                        1,565 (0.9)                                                                           376,405 (0.7)
  Lorazepam[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                         6,375 (3.8)                                                        2,237 (1.3)                                                                           2,139,238 (4.0)
  Triazolam[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                         4,625 (2.8)                                                        497 (0.3)                                                                             45,044 (0.1)
  Nifedipine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                        3,779 (2.3)                                                        1,255 (0.8)                                                                           528,204 (1.0)
  Clonazepam[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                        3,471 (2.1)                                                        204 (0.1)                                                                             1,488,470 (2.8)
  Ketorolac[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                         1,878 (1.1)                                                        5,594 (3.4)                                                                           543,586 (1.0)
  Megestrol[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                         1,775 (1.1)                                                        327 (0.2)                                                                             263,577 (0.5)
  Paroxetine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                        1,343 (0.8)                                                        39 (0.0)                                                                              852,918 (1.6)
  Cyclobenzaprine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                   1,335 (0.8)                                                        67 (0.0)                                                                              1,296,038 (2.4)
  Imipramine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                        1,307 (0.8)                                                        51 (0.0)                                                                              67,450 (0.1)
  Phenobarbital[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                     889 (0.5)                                                          105 (0.1)                                                                             77,327 (0.1)
  Clemastine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                        771 (0.5)                                                          83 (0.0)                                                                              3,457 (0.0)
  Chlordiazepoxide[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                  743 (0.4)                                                          63 (0.0)                                                                              30,182 (0.1)
  Benztropine (oral) [^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}               743 (0.4)                                                          51 (0.0)                                                                              306,664 (0.6)
  Ticlopidine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                       713 (0.4)                                                          32 (0.0)                                                                              3,375 (0.0)
  Flurazepam[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                        632 (0.4)                                                          120 (0.1)                                                                             18,289 (0.0)
  Clidinium-Chlordiazepoxide[^✝^](#t002fn003){ref-type="table-fn"}                                                418 (0.3)                                                          27 (0.0)                                                                              NA
  Trihexyphenidyl[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                   398 (0.2)                                                          22 (0.0)                                                                              47,580 (0.1)
  Clorazepate[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                       365 (0.2)                                                          14 (0.0)                                                                              70,224 (0.1)
  Triprolidine[^✝^](#t002fn003){ref-type="table-fn"}                                                              301 (0.2)                                                          23 (0.0)                                                                              NA
  Doxylamine[^✝^](#t002fn003){ref-type="table-fn"}                                                                212 (0.1)                                                          17 (0.0)                                                                              NA
  Atropine (excludes ophthalmic) [^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}   182 (0.1)                                                          3,542 (2.1)                                                                           368,693 (0.7)
  Clomipramine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                      86 (0.1)                                                           1 (0.0)                                                                               17,988 (0.0)
  Amoxapine[^✝^](#t002fn003){ref-type="table-fn"}^,^[\*](#t002fn002){ref-type="table-fn"}                         20 (0.0)                                                           1 (0.0)                                                                               2,099 (0.0)
  Pentazocine[^✝^](#t002fn003){ref-type="table-fn"}                                                               10 (0.0)                                                           2 (0.0)                                                                               5,483 (0.0)
  Dipyridamole (oral, short-acting)[\*](#t002fn002){ref-type="table-fn"}                                          4 (0.0)                                                            0 (0)                                                                                 135,045 (0.2)
  Pentobarbital                                                                                                   1 (0.0)                                                            0 (0)                                                                                 NA
  Amobarbital                                                                                                     0 (0)                                                              0 (0)                                                                                 NA
  Brompheniramine                                                                                                 0 (0)                                                              0 (0)                                                                                 NA
  Dexbrompheniramine                                                                                              0 (0)                                                              0 (0)                                                                                 NA
  Dexchlorpheniramine                                                                                             0 (0)                                                              0 (0)                                                                                 NA
  Guanabenz                                                                                                       0 (0)                                                              0 (0)                                                                                 NA
  Isoxsuprine                                                                                                     0 (0)                                                              0 (0)                                                                                 NA
  Mephobarbital                                                                                                   0 (0)                                                              0 (0)                                                                                 NA
  Mineral oil, given orally                                                                                       0 (0)                                                              0 (0)                                                                                 NA
  Quazepam                                                                                                        0 (0)                                                              0 (0)                                                                                 NA
  Meclizine[\*](#t002fn002){ref-type="table-fn"}                                                                  0 (0)                                                              0 (0)                                                                                 1,069,961 (2.0)
  Temazepam[\*](#t002fn002){ref-type="table-fn"}                                                                  0 (0)                                                              0 (0)                                                                                 714,706 (1.3)
  Promethazine[\*](#t002fn002){ref-type="table-fn"}                                                               0 (0)                                                              0 (0)                                                                                 695,648 (1.3)
  Dicyclomine[\*](#t002fn002){ref-type="table-fn"}                                                                0 (0)                                                              0 (0)                                                                                 535,628 (1.0)
  Glyburide[\*](#t002fn002){ref-type="table-fn"}                                                                  0 (0)                                                              0 (0)                                                                                 346,562 (0.6)
  Nortriptyline[\*](#t002fn002){ref-type="table-fn"}                                                              0 (0)                                                              0 (0)                                                                                 324,594 (0.6)
  Carisoprodol[\*](#t002fn002){ref-type="table-fn"}                                                               0 (0)                                                              0 (0)                                                                                 287,184 (0.5)
  Indomethacin[\*](#t002fn002){ref-type="table-fn"}                                                               0 (0)                                                              0 (0)                                                                                 193,060 (0.4)
  Eszopiclone[\*](#t002fn002){ref-type="table-fn"}                                                                0 (0)                                                              0 (0)                                                                                 113,047 (0.2)
  Scopolamine[\*](#t002fn002){ref-type="table-fn"}                                                                0 (0)                                                              0 (0)                                                                                 101,220 (0.2)
  Metaxalone[\*](#t002fn002){ref-type="table-fn"}                                                                 0 (0)                                                              0 (0)                                                                                 80,983 (0.1)
  Zaleplon[\*](#t002fn002){ref-type="table-fn"}                                                                   0 (0)                                                              0 (0)                                                                                 72,811 (0.1)
  Cyproheptadine[\*](#t002fn002){ref-type="table-fn"}                                                             0 (0)                                                              0 (0)                                                                                 63,651 (0.1)
  Desiccated thyroid[\*](#t002fn002){ref-type="table-fn"}                                                         0 (0)                                                              0 (0)                                                                                 51,167 (0.1)
  Chlorzoxazone[\*](#t002fn002){ref-type="table-fn"}                                                              0 (0)                                                              0 (0)                                                                                 30,151 (0.1)
  Guanfacine[\*](#t002fn002){ref-type="table-fn"}                                                                 0 (0)                                                              0 (0)                                                                                 29,973 (0.1)
  Butalbital[\*](#t002fn002){ref-type="table-fn"}                                                                 0 (0)                                                              0 (0)                                                                                 29,554 (0.1)
  Hyoscyamine[\*](#t002fn002){ref-type="table-fn"}                                                                0 (0)                                                              0 (0)                                                                                 24,939 (0.0)
  Oxazepam[\*](#t002fn002){ref-type="table-fn"}                                                                   0 (0)                                                              0 (0)                                                                                 21,717 (0.0)
  Desipramine[\*](#t002fn002){ref-type="table-fn"}                                                                0 (0)                                                              0 (0)                                                                                 20,551 (0.0)
  Estazolam[\*](#t002fn002){ref-type="table-fn"}                                                                  0 (0)                                                              0 (0)                                                                                 16,951 (0.0)
  Diphenhydramine (oral)[\*](#t002fn002){ref-type="table-fn"}                                                     0 (0)                                                              0 (0)                                                                                 16,007 (0.0)
  Methyldopa[\*](#t002fn002){ref-type="table-fn"}                                                                 0 (0)                                                              0 (0)                                                                                 13,878 (0.0)
  Meperidine[\*](#t002fn002){ref-type="table-fn"}                                                                 0 (0)                                                              0 (0)                                                                                 13,119 (0.0)
  Disopyramide[\*](#t002fn002){ref-type="table-fn"}                                                               0 (0)                                                              0 (0)                                                                                 4,729 (0.0)
  Carbinoxamine[\*](#t002fn002){ref-type="table-fn"}                                                              0 (0)                                                              0 (0)                                                                                 4,192 (0.0)
  Meprobamate[\*](#t002fn002){ref-type="table-fn"}                                                                0 (0)                                                              0 (0)                                                                                 3,595 (0.0)
  Protriptyline[\*](#t002fn002){ref-type="table-fn"}                                                              0 (0)                                                              0 (0)                                                                                 2,340 (0.0)
  Propantheline                                                                                                   0 (0)                                                              0 (0)                                                                                 1,058 (0.0)
  Chlorpropamide                                                                                                  0 (0)                                                              0 (0)                                                                                 634 (0.0)
  Belladonna alkaloids                                                                                            0 (0)                                                              0 (0)                                                                                 565 (0.0)
  Ergoloid mesylates                                                                                              0 (0)                                                              0 (0)                                                                                 500 (0.0)
  Trimipramine                                                                                                    0 (0)                                                              0 (0)                                                                                 323 (0.0)
  Butabarbital                                                                                                    0 (0)                                                              0 (0)                                                                                 283 (0.0)
  Secobarbital                                                                                                    0 (0)                                                              0 (0)                                                                                 61 (0.0)
  Reserpine                                                                                                       0 (0)                                                              0 (0)                                                                                 11 (0.0)
  Doxepin \>6 mg/d                                                                                                NA                                                                 NA                                                                                    NA
  Insulin, sliding scale                                                                                          NA                                                                 NA                                                                                    NA

*NA* not available, *BCM* Beers Criteria medication

\*Med prescribing frequency is significantly different between South Korean geriatrics on BCM \>1 day and US geriatrics according to Chi-square test (*P*\<0.05).

✝Med prescribing frequency is significantly different between South Korean geriatrics on BCM \>1 day and ≤1 day according to Chi-square test (*P*\<0.05).

Population at risk of ADE from study medications {#sec017}
------------------------------------------------

We estimated the number as well as proportion of geriatrics at risk of ADEs using the incidence rate of ADEs from BCMs in the literature and the exposure of the geriatrics to the BCMs. The number of study BCMs with ADE rates available in the literature was 16 out of 82 for Asians and 44 out of 82 for the US population. The ADE incidence rates and the number of South Korean patients at risk of the ADEs calculated using Eq ([1](#pone.0191376.e001){ref-type="disp-formula"}) are in [Table 3](#pone.0191376.t003){ref-type="table"} and of the US patients in [Table 4](#pone.0191376.t004){ref-type="table"}. The BCMs and ADEs in Tables [3](#pone.0191376.t003){ref-type="table"} and [4](#pone.0191376.t004){ref-type="table"} were sorted by the number of geriatrics at risk of the ADE. Specifically, for [Table 3](#pone.0191376.t003){ref-type="table"} the BCMs and ADEs were sorted by the number of South Korean geriatrics on BCMs \>1 day at risk of ADEs. The BCM-ADE pair with the highest number of South Koreans on BCMs \>1 day at risk of its occurrence was amitriptyline related dry mouth (n = 8,185, 4.9%) followed by amitriptyline related sleepiness (n = 7,508, 4.5%). In addition, dizziness and constipation from amitriptyline and rash/urticaria/pruritus, dizziness/somnolence, dyspnea, and nausea/vomiting from diazepam were among the ten most frequent ADEs that were predicted occur in this South Korean geriatric population on BCMs for for more than 1 day. The BCM-ADE pair with the highest number of South Koreans on BCMs ≤1 day at risk of its occurrence was diazepam related rash/urticaria/pruritus (n = 1,081, 0.6%). This was followed by lorazepam related dizziness/somnolence (n = 1,040, 0.6%), diazepam related dizziness/somnolence (n = 1,021, 0.6%), and diazepam related dyspnea (n = 873, 0.5%). The ADE from BCMs that the highest number of US geriatrics was at risk of was cyclobenzaprine related somnolence (n = 1,296,038, 2.4%). This was followed by cyclobenzaprine related dry mouth (n = 751,702, 1.4%), dicyclomine related dizziness/blurring of vision/dry mouth (n = 368,512, 0.7%), cyclobenzaprine related headache (n = 349,930, 0.6%), and lorazepam related restlessness (n = 320,886, 0.6%).

10.1371/journal.pone.0191376.t003

###### Rate and number of the geriatric population in South Korea at risk of adverse drug events from Beers Criteria medications (80 BCM-ADE pairs).
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  BCM (n = 16)       ADE (n = 56)                        Incidence of ADE in Asians (%)   No. South Korean geriatrics with risk of ADE (total no. 166,822)   SOC of ADE (per MedDRA ontology)   Reference of ADE incidence                                                                              
  ------------------ ----------------------------------- -------------------------------- ------------------------------------------------------------------ ---------------------------------- ------------------------------------------------------------------------------------------------------- ----------------------------
  Amitriptyline      Dry mouth                           75                               8,185                                                              413                                Gastrointestinal disorders                                                                              \[[@pone.0191376.ref016]\]
  Amitriptyline      Sleepiness                          68.8                             7,508                                                              379                                Psychiatric disorders                                                                                   \[[@pone.0191376.ref016]\]
  Diazepam           Rash/urticaria/pruritus             14.1                             5,569                                                              1,081                              Skin and subcutaneous tissue disorders/immune system disorders/skin and subcutaneous tissue disorders   \[[@pone.0191376.ref017]\]
  Diazepam           Dizziness/somnolence                13.3                             5,261                                                              1,021                              Nervous system disorders/psychiatric disorders                                                          \[[@pone.0191376.ref017]\]
  Dimenhydrinate     Weakness                            26                               5,049                                                              517                                General disorders and administration site conditions                                                    \[[@pone.0191376.ref018]\]
  Diazepam           Dyspnea                             11.4                             4,499                                                              873                                Cardiac disorders                                                                                       \[[@pone.0191376.ref017]\]
  Lorazepam          Dizziness/somnolence                46.5                             2,964                                                              1,040                              Nervous system disorders/psychiatric disorders                                                          \[[@pone.0191376.ref017]\]
  Amitriptyline      Dizziness                           25                               2,728                                                              138                                Nervous system disorders                                                                                \[[@pone.0191376.ref016]\]
  Diazepam           Nausea/vomiting                     6.3                              2,467                                                              479                                Gastrointestinal disorders                                                                              \[[@pone.0191376.ref017]\]
  Amitriptyline      Constipation                        18.8                             2,052                                                              104                                Gastrointestinal disorders                                                                              \[[@pone.0191376.ref016]\]
  Lorazepam          Hypotension                         27.1                             1,728                                                              606                                Vascular disorders                                                                                      \[[@pone.0191376.ref017]\]
  Lorazepam          Dyspnea                             26.3                             1,678                                                              589                                Cardiac disorders                                                                                       \[[@pone.0191376.ref017]\]
  Dimenhydrinate     Dizziness                           8                                1,554                                                              159                                Nervous system disorders                                                                                \[[@pone.0191376.ref018]\]
  Lorazepam          Rash/urticaria/ pruritus            22.6                             1,439                                                              505                                Skin and subcutaneous tissue disorders/immune system disorders/skin and subcutaneous tissue disorders   \[[@pone.0191376.ref017]\]
  Clonazepam         Drowsiness                          36.8                             1,277                                                              75                                 Psychiatric disorders                                                                                   \[[@pone.0191376.ref019]\]
  Lorazepam          Nausea/vomiting                     14.2                             902                                                                317                                Gastrointestinal disorders                                                                              \[[@pone.0191376.ref017]\]
  Amitriptyline      Palpitations                        6.3                              688                                                                35                                 Cardiac disorders                                                                                       \[[@pone.0191376.ref016]\]
  Amitriptyline      Malaise                             6.3                              688                                                                35                                 General disorders and administration site conditions                                                    \[[@pone.0191376.ref016]\]
  Diazepam           Hypotension                         1.4                              560                                                                109                                Vascular disorders                                                                                      \[[@pone.0191376.ref017]\]
  Dimenhydrinate     Drowsiness                          2                                388                                                                40                                 Psychiatric disorders                                                                                   \[[@pone.0191376.ref018]\]
  Zolpidem           Impaired balance/falls              1.8                              257                                                                33                                 Nervous system disorders/injury, poisoning and procedural complications                                 \[[@pone.0191376.ref020]\]
  Nifedipine         Mild headache                       6.7                              253                                                                84                                 Nervous system disorders                                                                                \[[@pone.0191376.ref021]\]
  Zolpidem           Morning drowsiness                  1.3                              186                                                                24                                 Psychiatric disorders                                                                                   \[[@pone.0191376.ref020]\]
  Clonazepam         Dizziness                           5.3                              184                                                                11                                 Nervous system disorders                                                                                \[[@pone.0191376.ref019]\]
  Phenobarbital      Weight gain                         14.7                             131                                                                15                                 Investigations                                                                                          \[[@pone.0191376.ref022]\]
  Paroxetine         Loss of appetite                    8.7                              117                                                                3                                  Metabolism and nutrition disorders                                                                      \[[@pone.0191376.ref023]\]
  Paroxetine         Nausea and vomiting                 8.7                              117                                                                3                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref023]\]
  Zolpidem           Amnesia                             0.8                              114                                                                15                                 Nervous system disorders                                                                                \[[@pone.0191376.ref020]\]
  Zolpidem           Agitation/confusion/ somnambulism   0.7                              100                                                                13                                 Nervous system disorders/psychiatric disorders/nervous system disorders                                 \[[@pone.0191376.ref020]\]
  Phenobarbital      Nausea, vomiting                    10.3                             92                                                                 11                                 Gastrointestinal disorders                                                                              \[[@pone.0191376.ref022]\]
  Paroxetine         Dry mouth                           6.5                              87                                                                 3                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref023]\]
  Paroxetine         Sweating                            6.5                              87                                                                 3                                  General disorders and administration site conditions                                                    \[[@pone.0191376.ref023]\]
  Zolpidem           Twilight state                      0.5                              71                                                                 9                                  Nervous system disorders                                                                                \[[@pone.0191376.ref023]\]
  Paroxetine         Dizziness                           4.3                              58                                                                 2                                  Nervous system disorders                                                                                \[[@pone.0191376.ref020]\]
  Zolpidem           Dizziness                           0.4                              57                                                                 7                                  Nervous system disorders                                                                                \[[@pone.0191376.ref020]\]
  Zolpidem           Dependence                          0.4                              57                                                                 7                                  Psychiatric disorders                                                                                   \[[@pone.0191376.ref020]\]
  Paroxetine         Weight gain                         2.2                              30                                                                 1                                  Investigations                                                                                          \[[@pone.0191376.ref023]\]
  Paroxetine         Blurred vision                      2.2                              30                                                                 1                                  Nervous system disorders                                                                                \[[@pone.0191376.ref023]\]
  Zolpidem           Headache                            0.2                              29                                                                 4                                  Nervous system disorders                                                                                \[[@pone.0191376.ref020]\]
  Zolpidem           Nightmare                           0.2                              29                                                                 4                                  Psychiatric disorders                                                                                   \[[@pone.0191376.ref020]\]
  Zolpidem           Malaise                             0.2                              29                                                                 4                                  General disorders and administration site conditions                                                    \[[@pone.0191376.ref020]\]
  Zolpidem           Weakness                            0.2                              29                                                                 4                                  General disorders and administration site conditions                                                    \[[@pone.0191376.ref020]\]
  Ticlopidine        Cerebral infarction                 2.5                              18                                                                 1                                  Nervous system disorders                                                                                \[[@pone.0191376.ref024]\]
  Zolpidem           Dysgeusia                           0.1                              14                                                                 2                                  Nervous system disorders                                                                                \[[@pone.0191376.ref020]\]
  Phenobarbital      Hepatitis                           1.5                              13                                                                 2                                  Hepatobiliary disorders                                                                                 \[[@pone.0191376.ref022]\]
  Ticlopidine        Transient ischemic attack           0.5                              4                                                                  0                                  Vascular disorders                                                                                      \[[@pone.0191376.ref024]\]
  Ticlopidine        Angina pectoris                     0.4                              3                                                                  0                                  Coronary artery disorders                                                                               \[[@pone.0191376.ref024]\]
  Ticlopidine        Peripheral arterial occlusion       0.1                              1                                                                  0                                  Vascular disorders                                                                                      \[[@pone.0191376.ref024]\]
  Estazolam          Falls                               16.1                             0                                                                  0                                  Injury, poisoning and procedural complications                                                          \[[@pone.0191376.ref025]\]
  Eszopiclone        Dysgeusia                           16.2                             0                                                                  0                                  Nervous system disorders                                                                                \[[@pone.0191376.ref026]\]
  Eszopiclone        Somnolence                          5.9                              0                                                                  0                                  Psychiatric disorders                                                                                   \[[@pone.0191376.ref026]\]
  Eszopiclone        Dizziness                           2.9                              0                                                                  0                                  Nervous system disorders                                                                                \[[@pone.0191376.ref026]\]
  Eszopiclone        Dermatitis contact                  2.9                              0                                                                  0                                  Injury, poisoning and procedural complications                                                          \[[@pone.0191376.ref026]\]
  Eszopiclone        Feeling abnormal                    4.3                              0                                                                  0                                  General disorders and administration site conditions                                                    \[[@pone.0191376.ref026]\]
  Isoxsuprine        Decreased arterial pressure         22.2                             0                                                                  0                                  Investigations                                                                                          \[[@pone.0191376.ref027]\]
  Isoxsuprine        Headache                            19.4                             0                                                                  0                                  Nervous system disorders                                                                                \[[@pone.0191376.ref027]\]
  Isoxsuprine        Trembling                           8.3                              0                                                                  0                                  Nervous system disorders                                                                                \[[@pone.0191376.ref027]\]
  Isoxsuprine        Nervousness                         11.1                             0                                                                  0                                  Psychiatric disorders                                                                                   \[[@pone.0191376.ref027]\]
  Isoxsuprine        Gastrointestinal problems           25.0                             0                                                                  0                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref027]\]
  Isoxsuprine        Skin rash                           11.1                             0                                                                  0                                  Skin and subcutaneous tissue disorders                                                                  \[[@pone.0191376.ref027]\]
  Isoxsuprine        Facial redness                      11.1                             0                                                                  0                                  Skin and subcutaneous tissue disorders                                                                  \[[@pone.0191376.ref027]\]
  Isoxsuprine        Tachycardia                         5.6                              0                                                                  0                                  Cardiac disorders                                                                                       \[[@pone.0191376.ref027]\]
  Meperidine         Shivering                           9.1                              0                                                                  0                                  Musculoskeletal and connective tissue disorders                                                         \[[@pone.0191376.ref028]\]
  Meperidine         Nausea                              21.2                             0                                                                  0                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref028]\]
  Meperidine         Pruritus                            3.0                              0                                                                  0                                  Skin and subcutaneous tissue disorders                                                                  \[[@pone.0191376.ref028]\]
  Nortriptyline      Dysarthria                          36.8                             0                                                                  0                                  Psychiatric disorders                                                                                   \[[@pone.0191376.ref029]\]
  Nortriptyline      Orthostatic dizziness               42.1                             0                                                                  0                                  Nervous system disorders                                                                                \[[@pone.0191376.ref029]\]
  Nortriptyline      Sleepiness/sedation                 47.4                             0                                                                  0                                  Psychiatric disorders/nervous system disorders                                                          \[[@pone.0191376.ref029]\]
  Nortriptyline      Accommodation disturbance           36.8                             0                                                                  0                                  Eye disorders                                                                                           \[[@pone.0191376.ref029]\]
  Nortriptyline      Reducded salivation                 60.5                             0                                                                  0                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref029]\]
  Nortriptyline      Diarrhea                            23.7                             0                                                                  0                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref029]\]
  Nortriptyline      Constipation                        50.0                             0                                                                  0                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref029]\]
  Nortriptyline      Micturition disturbance             39.5                             0                                                                  0                                  Renal and urinary disorders                                                                             \[[@pone.0191376.ref029]\]
  Nortriptyline      Nausea/vomiting                     15.8                             0                                                                  0                                  Gastrointestinal disorders                                                                              \[[@pone.0191376.ref029]\]
  Nortriptyline      Weight gain                         39.5                             0                                                                  0                                  Investigations                                                                                          \[[@pone.0191376.ref029]\]
  Nortriptyline      Weight loss                         10.5                             0                                                                  0                                  Investigations                                                                                          \[[@pone.0191376.ref029]\]
  Nortriptyline      Diminished sexual desire            36.8                             0                                                                  0                                  Reproductive system and breast disorders                                                                \[[@pone.0191376.ref029]\]
  Doxepin \>6 mg/d   Somnolence                          14.2                             NA                                                                 NA                                 Psychiatric disorders                                                                                   \[[@pone.0191376.ref030]\]
  Doxepin \>6 mg/d   Nervousness                         2.9                              NA                                                                 NA                                 Psychiatric disorders                                                                                   \[[@pone.0191376.ref030]\]

*NA* not available, *BCM* Beers Criteria medication.

10.1371/journal.pone.0191376.t004

###### Rate and number of the geriatric population in the US at risk of adverse drug events from Beers Criteria medications (159 BCM-ADE pairs).

![](pone.0191376.t004){#pone.0191376.t004g}

  BCM (n = 44)                       ADE (n = 104)                                                                                                Incidence of ADE in US (%)   No. US geriatrics with risk of ADE (total no. 54,095,565)   SOC of ADE (per MedDRA ontology)                                                                                                                                                                                                                                                         Reference of ADE incidence
  ---------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Cyclobenzaprine                    Somnolence                                                                                                   100                          1,296,038                                                   Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref031]\]
  Cyclobenzaprine                    Dry mouth                                                                                                    58                           751,702                                                     Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref031]\]
  Dicyclomine                        Dizziness/blurring of vision/dry mouth                                                                       68.8                         368,512                                                     Nervous system disorders/nervous system disorders/gastrointestinal disorders                                                                                                                                                                                                             \[[@pone.0191376.ref032]\]
  Cyclobenzaprine                    Headache                                                                                                     27                           349,930                                                     Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref031]\]
  Lorazepam                          restlessness                                                                                                 15                           320,886                                                     Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref033]\]
  Atropine (excludes ophthalmic)     Fatigue                                                                                                      84.6                         311,914                                                     General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref034]\]
  Cyclobenzaprine                    Dizziness                                                                                                    19                           246,247                                                     Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref031]\]
  Atropine (excludes ophthalmic)     Dyspnea                                                                                                      53.8                         198,357                                                     Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref034]\]
  Benztropine (oral)                 Dry mouth                                                                                                    63                           193,198                                                     Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref035]\]
  Cyclobenzaprine                    Blurred vision                                                                                               12                           155,525                                                     Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref031]\]
  Benztropine (oral)                 Blurred vision                                                                                               42                           128,799                                                     Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref035]\]
  Atropine (excludes ophthalmic)     Dry mouth                                                                                                    34.6                         127,568                                                     Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref034]\]
  Clonazepam                         Fatigue                                                                                                      8                            119,078                                                     General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref036]\]
  Cyclobenzaprine                    Dry throat                                                                                                   8                            103,683                                                     Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref031]\]
  Cyclobenzaprine                    Nausea                                                                                                       8                            103,683                                                     Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref031]\]
  Paroxetine                         Hyponatremia                                                                                                 12                           102,350                                                     Metabolism and nutrition disorders                                                                                                                                                                                                                                                       \[[@pone.0191376.ref037]\]
  Clonazepam                         Hypotonia                                                                                                    6                            89,308                                                      Musculoskeletal and connective tissue disorders                                                                                                                                                                                                                                          \[[@pone.0191376.ref036]\]
  Benztropine (oral)                 Decreased motor activity                                                                                     26                           79,733                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref035]\]
  Benztropine (oral)                 Dizziness                                                                                                    26                           79,733                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref035]\]
  Benztropine (oral)                 Drowsiness                                                                                                   24                           73,599                                                      Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref035]\]
  Benztropine (oral)                 Anorexia                                                                                                     20                           61,333                                                      Metabolism and nutrition disorders                                                                                                                                                                                                                                                       \[[@pone.0191376.ref035]\]
  Imipramine                         Constipation                                                                                                 65                           43,843                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref038]\]
  Atropine (excludes ophthalmic)     Angina                                                                                                       11.5                         42,400                                                      Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref034]\]
  Benztropine (oral)                 Nausea                                                                                                       13                           39,866                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref035]\]
  Cyproheptadine                     Sedation                                                                                                     62.5                         39,782                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref039]\]
  Nifedipine                         Edema                                                                                                        7.5                          39,615                                                      Metabolism and nutrition disorders                                                                                                                                                                                                                                                       \[[@pone.0191376.ref040]\]
  Triazolam                          Next-day memory impairment/amnesia                                                                           83.3                         37,522                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref041]\]
  Imipramine                         Dry mouth                                                                                                    55                           37,098                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref038]\]
  Zolpidem                           Nonvertebral fracture                                                                                        1.7                          36,289                                                      Injury, poisoning and procedural complications                                                                                                                                                                                                                                           \[[@pone.0191376.ref042]\]
  Cyproheptadine                     Dry mouth                                                                                                    56.3                         35,836                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref039]\]
  Nortriptyline                      Sinus tachycardia                                                                                            10                           32,459                                                      Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref043]\]
  Atropine (excludes ophthalmic)     Palpitations                                                                                                 7.7                          28,389                                                      Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref034]\]
  Imipramine                         Tremor                                                                                                       40                           26,980                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref038]\]
  Imipramine                         Drowsiness                                                                                                   40                           26,980                                                      Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref038]\]
  Diazepam                           Headache                                                                                                     2.5                          26,942                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref044]\]
  Diazepam                           Agitation                                                                                                    2.5                          26,942                                                      Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref044]\]
  Imipramine                         Sweating                                                                                                     35                           23,608                                                      General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref038]\]
  Imipramine                         Vertigo                                                                                                      35                           23,608                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref038]\]
  Imipramine                         Headache                                                                                                     35                           23,608                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref038]\]
  Imipramine                         Cardiovascular symptoms                                                                                      35                           23,608                                                      Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref038]\]
  Zolpidem                           Hip fracture                                                                                                 1.1                          23,481                                                      Injury, poisoning and procedural complications                                                                                                                                                                                                                                           \[[@pone.0191376.ref042]\]
  Benztropine (oral)                 Sweating                                                                                                     7                            21,466                                                      General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref035]\]
  Imipramine                         Disturbance of accomodation                                                                                  30                           20,235                                                      Eye disorders                                                                                                                                                                                                                                                                            \[[@pone.0191376.ref038]\]
  Ketorolac                          Tachycardia                                                                                                  3.5                          19,026                                                      Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref045]\]
  Desipramine                        Tiredness                                                                                                    89.5                         18,393                                                      General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref046]\]
  Clorazepate                        Drowsiness                                                                                                   26                           18,258                                                      Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref047]\]
  Nifedipine                         Headache                                                                                                     3.4                          17,959                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref040]\]
  Desipramine                        Dry mouth                                                                                                    84.2                         17,304                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref046]\]
  Desiccated thyroid                 Hypertriiodothyroninemia                                                                                     33.3                         17,039                                                      Investigations                                                                                                                                                                                                                                                                           \[[@pone.0191376.ref048]\]
  Temazepam                          Fatigue/sensation of heaviness/somnolence/eye irritation                                                     2.3                          16,367                                                      General disorders and administration site conditions/general disorders and administration site conditions/psychiatric disorders/eye disorders                                                                                                                                            \[[@pone.0191376.ref049]\]
  Nortriptyline                      Intractable constipation                                                                                     5                            16,230                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref043]\]
  Nortriptyline                      Proarrhythmic event                                                                                          5                            16,230                                                      Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref043]\]
  Ketorolac                          Hypotension                                                                                                  2.8                          15,220                                                      Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref045]\]
  Eszopiclone                        Unpleasant taste                                                                                             12.5                         14,131                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref050]\]
  Nifedipine                         Dizziness                                                                                                    2.6                          13,733                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref040]\]
  Imipramine                         Disturbance of micturition                                                                                   20                           13,490                                                      Renal and urinary disorders                                                                                                                                                                                                                                                              \[[@pone.0191376.ref038]\]
  Imipramine                         Nausea                                                                                                       20                           13,490                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref038]\]
  Diazepam                           Somnolence                                                                                                   1.2                          12,932                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref044]\]
  Megestrol                          Deep vein thrombosis                                                                                         4.9                          12,915                                                      Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref051]\]
  Cyproheptadine                     Dizziness                                                                                                    18.8                         11,966                                                      Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref039]\]
  Cyproheptadine                     Nausea and vomiting                                                                                          18.8                         11,966                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref039]\]
  Hyoscyamine                        Dry mouth/constipation/dizziness/tiredness/headaches/vaginal dryness/night sweats                            61.3                         11,912                                                      Gastrointestinal disorders/gastrointestinal disorders/nervous system disorders/general disorders and administration site conditions/nervous system disorders/reproductive system and breast disorders/general disorders and administration site conditions                               \[[@pone.0191376.ref052]\]
  Ketorolac                          Hypertension                                                                                                 2.1                          11,415                                                      Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref045]\]
  Ketorolac                          Thrombophlebitis                                                                                             2.1                          11,415                                                      Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref045]\]
  Desipramine                        Constipation                                                                                                 55.3                         11,365                                                      Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref046]\]
  Glyburide                          Edema                                                                                                        3.2                          11,090                                                      Metabolism and nutrition disorders                                                                                                                                                                                                                                                       \[[@pone.0191376.ref053]\]
  Imipramine                         Sexual dysfunctions                                                                                          15                           10,118                                                      Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref038]\]
  Eszopiclone                        Dry mouth                                                                                                    8.8                          9,948                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref050]\]
  Flurazepam                         Hangover symptoms                                                                                            50                           9,145                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref054]\]
  Dipyridamole (oral short-acting)   Chest pain/headache/nausea/dizziness/pain (not chest)/dyspnea/vomiting/wheezing/syncope/severe hypotension   36                           8,766                                                       Cardiac disorders/nervous system disorders/gastrointestinal disorders/nervous system disorders/general disorders and administration site conditions/cardiac disorders/gastrointestinal disorders/respiratory, thoracic and mediastinal disorders/vascular disorders/vascular disorders   \[[@pone.0191376.ref055]\]
  Nifedipine                         Constipation                                                                                                 1.6                          8,451                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref040]\]
  Glyburide                          Weight gain                                                                                                  2.4                          8,317                                                       Investigations                                                                                                                                                                                                                                                                           \[[@pone.0191376.ref053]\]
  Nortriptyline                      Persistent myoclonic jerks                                                                                   2.5                          8,115                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref043]\]
  Nortriptyline                      Severe angina                                                                                                2.5                          8,115                                                       Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref043]\]
  Nifedipine                         Fatigue                                                                                                      1.5                          7,923                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref040]\]
  Chlordiazepoxide                   Drowsy                                                                                                       25.8                         7,787                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref056]\]
  Eszopiclone                        Dizziness                                                                                                    6.6                          7,461                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref050]\]
  Eszopiclone                        Somnolence                                                                                                   6.6                          7,461                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref050]\]
  Guanfacine                         Fatigue                                                                                                      23.5                         7,044                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref057]\]
  Desipramine                        Insomnia                                                                                                     34.2                         7,028                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref046]\]
  Desipramine                        Increased sweating                                                                                           34.2                         7,028                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref046]\]
  Clorazepate                        Depression                                                                                                   10                           7,022                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref047]\]
  Imipramine                         Ataxia                                                                                                       10                           6,745                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref038]\]
  Imipramine                         Vomiting                                                                                                     10                           6,745                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref038]\]
  Eszopiclone                        Pain                                                                                                         5.9                          6,670                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref050]\]
  Diphenhydramine (oral)             Delirium symptoms                                                                                            41.2                         6,595                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref058]\]
  Desipramine                        Headache                                                                                                     28.9                         5,939                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref046]\]
  Desipramine                        Lightheadedness                                                                                              28.9                         5,939                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref046]\]
  Clomipramine                       Dry mouth                                                                                                    32.2                         5,792                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref059]\]
  Estazolam                          Drugged feeling                                                                                              33.3                         5,645                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref060]\]
  Nifedipine                         Chest pain                                                                                                   1                            5,282                                                       Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref040]\]
  Nifedipine                         Flushing                                                                                                     1                            5,282                                                       Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref040]\]
  Nifedipine                         Abdominal pain                                                                                               1                            5,282                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref040]\]
  Nifedipine                         Nausea                                                                                                       0.9                          4,754                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref040]\]
  Eszopiclone                        Nervousness                                                                                                  3.7                          4,183                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref050]\]
  Eszopiclone                        Rash                                                                                                         3.7                          4,183                                                       Skin and subcutaneous tissue disorders                                                                                                                                                                                                                                                   \[[@pone.0191376.ref050]\]
  Cyproheptadine                     Blurred vision                                                                                               6.3                          4,010                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref039]\]
  Ketorolac                          Angina pectoris                                                                                              0.7                          3,805                                                       Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref045]\]
  Ketorolac                          Cardiac failure congestive                                                                                   0.7                          3,805                                                       Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref045]\]
  Ketorolac                          Supraventricular tachycardia                                                                                 0.7                          3,805                                                       Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref045]\]
  Ketorolac                          Flushing                                                                                                     0.7                          3,805                                                       Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref045]\]
  Imipramine                         Increased energy                                                                                             5                            3,373                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref038]\]
  Eszopiclone                        Accidental injury                                                                                            2.9                          3,278                                                       Injury, poisoning and procedural complications                                                                                                                                                                                                                                           \[[@pone.0191376.ref050]\]
  Clomipramine                       Dizziness                                                                                                    15.9                         2,860                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref059]\]
  Glyburide                          Hypoglycemia                                                                                                 0.8                          2,772                                                       Metabolism and nutrition disorders                                                                                                                                                                                                                                                       \[[@pone.0191376.ref053]\]
  Clomipramine                       Constipation                                                                                                 14.6                         2,626                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref059]\]
  Pentazocine                        Drowsy/sleepy                                                                                                47.2                         2,588                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref061]\]
  Indomethacin                       Cardiovascular and cerebrovascular events                                                                    1.33                         2,568                                                       Vascular disorders/nervous system disorders                                                                                                                                                                                                                                              \[[@pone.0191376.ref062]\]
  Eszopiclone                        Back pain                                                                                                    2.2                          2,487                                                       Musculoskeletal and connective tissue disorders                                                                                                                                                                                                                                          \[[@pone.0191376.ref050]\]
  Eszopiclone                        Peripheral edema                                                                                             2.2                          2,487                                                       Metabolism and nutrition disorders                                                                                                                                                                                                                                                       \[[@pone.0191376.ref050]\]
  Eszopiclone                        Arthralgia                                                                                                   2.2                          2,487                                                       Musculoskeletal and connective tissue disorders                                                                                                                                                                                                                                          \[[@pone.0191376.ref050]\]
  Eszopiclone                        Anxiety                                                                                                      2.2                          2,487                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref050]\]
  Estazolam                          Dizziness                                                                                                    13.3                         2,254                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref060]\]
  Clomipramine                       Erectile dysfunction                                                                                         10.4                         1,871                                                       Reproductive system and breast disorders                                                                                                                                                                                                                                                 \[[@pone.0191376.ref059]\]
  Disopyramide                       Dry mouth                                                                                                    37                           1,750                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref063]\]
  Eszopiclone                        Emotional lability                                                                                           1.5                          1,696                                                       Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref050]\]
  Eszopiclone                        Memory impairment                                                                                            1.5                          1,696                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref050]\]
  Desipramine                        Orthostatic symptoms                                                                                         7.9                          1,624                                                       Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref046]\]
  Desipramine                        Palpitations                                                                                                 7.9                          1,624                                                       Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref046]\]
  Amoxapine                          Composite of anticholinergic symptoms/cardiovascular/neurological/sedative complaints                        68.1                         1,429                                                       Nervous system disorders/cardiac disorders                                                                                                                                                                                                                                               \[[@pone.0191376.ref064]\]
  Clorazepate                        Headache                                                                                                     2                            1,404                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref047]\]
  Disopyramide                       Headache                                                                                                     29.6                         1,400                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref063]\]
  Disopyramide                       Bowel changes                                                                                                29.6                         1,400                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref063]\]
  Diphenhydramine (oral)             Required new urinary catheter                                                                                7.9                          1,265                                                       Surgical and medical procedures                                                                                                                                                                                                                                                          \[[@pone.0191376.ref058]\]
  Disopyramide                       Urinary complaints                                                                                           25.9                         1,225                                                       Renal and urinary disorders                                                                                                                                                                                                                                                              \[[@pone.0191376.ref063]\]
  Disopyramide                       Weakness                                                                                                     22.2                         1,050                                                       General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref063]\]
  Disopyramide                       Nausea                                                                                                       22.2                         1,050                                                       Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref063]\]
  Disopyramide                       Palpitations                                                                                                 22.2                         1,050                                                       Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref063]\]
  Disopyramide                       Lightheadedness                                                                                              22.2                         1,050                                                       Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref063]\]
  Clomipramine                       Insomnia                                                                                                     4.2                          755                                                         Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref059]\]
  Propantheline                      Dry mouth                                                                                                    56.3                         596                                                         Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref065]\]
  Diphenhydramine (oral)             Behavioral disturbance                                                                                       3.5                          560                                                         Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref058]\]
  Estazolam                          Headache                                                                                                     3.3                          559                                                         Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref060]\]
  Estazolam                          Hangover                                                                                                     3.3                          559                                                         General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref060]\]
  Clomipramine                       Nervousness                                                                                                  2.9                          522                                                         Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref059]\]
  Promethazine                       Dystonia/extrapyrimidal symptoms/oversedation/delirium/ respiratory depression                               0.1                          401                                                         Nervous system disorders/nervous system disorders/nervous system disorders/psychiatric disorders/nervous system disorders                                                                                                                                                                \[[@pone.0191376.ref066]\]
  Butalbital                         Somnolence                                                                                                   1                            296                                                         Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref067]\]
  Butalbital                         Dizziness                                                                                                    1                            296                                                         Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref067]\]
  Diphenhydramine (oral)             Use of physical restraints                                                                                   1.8                          288                                                         Surgical and medical procedures                                                                                                                                                                                                                                                          \[[@pone.0191376.ref058]\]
  Protriptyline                      Dysuria                                                                                                      11.1                         260                                                         Renal and urinary disorders                                                                                                                                                                                                                                                              \[[@pone.0191376.ref068]\]
  Protriptyline                      Nervousness                                                                                                  11.1                         260                                                         Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref068]\]
  Pentazocine                        Nausea                                                                                                       2.8                          154                                                         Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref061]\]
  Butalbital                         Nausea                                                                                                       0.5                          148                                                         Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref067]\]
  Butalbital                         Nasopharyngitis                                                                                              0.5                          148                                                         Respiratory, thoracic and mediastinal disorders                                                                                                                                                                                                                                          \[[@pone.0191376.ref067]\]
  Propantheline                      Urinary hesitancy                                                                                            12.5                         132                                                         Renal and urinary disorders                                                                                                                                                                                                                                                              \[[@pone.0191376.ref065]\]
  Butalbital                         Paresthesia                                                                                                  0.3                          89                                                          Nervous system disorders                                                                                                                                                                                                                                                                 \[[@pone.0191376.ref067]\]
  Propantheline                      Spastic colon                                                                                                6.3                          67                                                          Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref065]\]
  Pentazocine                        Asleep                                                                                                       0.9                          49                                                          Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref061]\]
  Ticlopidine                        Rash                                                                                                         1                            32                                                          Skin and subcutaneous tissue disorders                                                                                                                                                                                                                                                   \[[@pone.0191376.ref069]\]
  Ticlopidine                        Thrombocytopenia                                                                                             0.6                          19                                                          Blood and lymphatic system disorders                                                                                                                                                                                                                                                     \[[@pone.0191376.ref069]\]
  Ticlopidine                        Bleeding                                                                                                     0.4                          13                                                          Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref069]\]
  Ticlopidine                        Gastrointestinal                                                                                             0.4                          13                                                          Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref069]\]
  Ticlopidine                        Neutropenia                                                                                                  0.4                          13                                                          Blood and lymphatic system disorders                                                                                                                                                                                                                                                     \[[@pone.0191376.ref069]\]
  Clemastine                         Life-threatening ventricular arrhythmias                                                                     0.1                          2                                                           Cardiac disorders                                                                                                                                                                                                                                                                        \[[@pone.0191376.ref070]\]
  Chlorpheniramine                   Drowsiness/nausea/euphoria                                                                                   25                           NA                                                          Psychiatric disorders/gastrointestinal disorders/psychiatric disorders                                                                                                                                                                                                                   \[[@pone.0191376.ref071]\]
  Guanabenz                          Dry mouth                                                                                                    37                           NA                                                          Gastrointestinal disorders                                                                                                                                                                                                                                                               \[[@pone.0191376.ref072]\]
  Guanabenz                          Drowsiness                                                                                                   13                           NA                                                          Psychiatric disorders                                                                                                                                                                                                                                                                    \[[@pone.0191376.ref072]\]
  Pentobarbital                      Hypotension                                                                                                  64.7                         NA                                                          Vascular disorders                                                                                                                                                                                                                                                                       \[[@pone.0191376.ref073]\]
  Quazepam                           Hangover symptoms                                                                                            54.5                         NA                                                          General disorders and administration site conditions                                                                                                                                                                                                                                     \[[@pone.0191376.ref054]\]

*NA* not available, *BCM* Beers Criteria medication.

The mean proportion of South Korean on BCMs for \>1 day versus ≤1 day at risk of ADEs grouped according to MedDRA SOC is in [Fig 2](#pone.0191376.g002){ref-type="fig"}. The mean proportion of South Korean on BCMs for \>1 day and US geriatrics at risk of ADEs grouped according to MedDRA SOC is in [Fig 3](#pone.0191376.g003){ref-type="fig"}. Out of the total 26 SOCs in MedDRA, the BCM ADEs which South Korean geriatrics (regardless of duration of BCM prescription) may be at risk from corresponded to 15 single SOCs and 4 multiple SOC combinations. The 15 single SOCs were "cardiac disorders", "eye disorders", "gastrointestinal disorders", "general disorders and administration site conditions", "hepatobiliary disorders", "injury, poisoning and procedural complications", "investigations", "metabolism and nutrition disorders", "Musculoskeletal and connective tissue disorders", "nervous system disorders", "psychiatric disorders", "renal and urinary disorders", "reproductive system and breast disorders", "skin and subcutaneous tissue disorders", and "vascular disorders". Seven BCM-ADE pairs included ADEs that were a composite of multiple ADEs that were grouped into more than one SOC.

![Mean (SD) proportion of South Koreans on Beers Criteria medications \>1 day and ≤1 day at risk of Beers Criteria medication related adverse drug events grouped by system organ class.\
The population number used as the denominator to obtain the proportion in the y-axis was the number of South Korean geriatrics 65 years of age or older, n = 166,822. The SOCs were *A* cardiac disorders (Beers Criteria medication-ADE pairs, n = 5); *B* eye disorders (n = 1); *C* gastrointestinal disorders (n = 13); *D* general disorders and administration site conditions (n = 6); *E* hepatobiliary disorders (n = 1); *F* injury, poisoning and procedural complications (n = 2); *G* investigations (n = 5); *H* metabolism and nutrition disorders (n = 1); *I* musculoskeletal and connective tissue disorders (n = 1); *J* nervous system disorders (n = 18); *K* psychiatric disorders (n = 11); *L* renal and urinary disorders (n = 1); *M* reproductive system and breast disorders (n = 1); *N* skin and subcutaneous tissue disorders (n = 3); *O* vascular disorders (n = 4); *P* composite of multiple SOCs (n = 7). *ADE* adverse drug event; *BCM* Beers Criteria medication; *SOC* system organ class; *SD* standard deviation.](pone.0191376.g002){#pone.0191376.g002}

![Mean (SD) proportion of South Koreans on Beers Criteria medications \>1 day and US geriatrics at risk of Beers Criteria medication related adverse drug events grouped by system organ class.\
The SOCs were *A* blood and lymphatic system disorders (Beers Criteria medication-ADE pairs, n = 0 for South Korea, n = 2 for US); *B* cardiac disorders (n = 5 for South Korea, n = 15 for US); *C* eye disorders (n = 1 for South Korea, n = 1 for US); *D* gastrointestinal disorders (n = 13 for South Korea, n = 30 for US); *E* general disorders and administration site conditions (n = 6 for South Korea, n = 15 for US); *F* hepatobiliary disorders (n = 1 for South Korea, n = 0 for US); *G* injury, poisoning and procedural complications (n = 2 for South Korea, n = 3 for US); *H* investigations (n = 5 for South Korea, n = 2 for US); *I* metabolism and nutrition disorders (n = 1 for South Korea, n = 6 for US); *J* musculoskeletal and connective tissue disorders (n = 1 for South Korea, n = 3 for US); *K* nervous system disorders (n = 18 for South Korea, n = 33 for US); *L* psychiatric disorders (n = 11 for South Korea, n = 22 for US); *M* renal and urinary disorders (n = 1 for South Korea, n = 4 for US); *N* reproductive system and breast disorders (n = 1 for South Korea, n = 1 for US); *O* respiratory, thoracic and mediastinal disorders (n = 0 for South Korea, n = 1 for US); *P* skin and subcutaneous tissue disorders (n = 3 for South Korea, n = 2 for US); *Q* surgical and medical procedures (n = 0 for South Korea, n = 2 for US); *R* vascular disorders (n = 4 for South Korea, n = 9 for US); *S* composite of multiple SOCs (n = 7 for South Korea, n = 8 for US). *ADE* adverse drug event; *SOC* system organ class; *SD* standard deviation.](pone.0191376.g003){#pone.0191376.g003}

The BCM ADEs which US geriatrics were at risk from corresponded to 17 single SOCs and 8 multiple SOC combinations. The single SOCs were "blood and lymphatic system disorders", "cardiac disorders", "eye disorders", "gastrointestinal disorders", "general disorders and administration site conditions", "injury, poisoning and procedural complications", "investigations", "metabolism and nutrition disorders", "musculoskeletal and connective tissue disorders", "nervous system disorders", "psychiatric disorders", "renal and urinary disorders", "reproductive system and breast disorders", "respiratory, thoracic and mediastinal disorders", "skin and subcutaneous tissue disorders", "surgical and medical procedures", and "vascular disorders". Eight BCM-ADE pairs included ADEs that were a composite of multiple ADEs that were grouped into more than one SOC.

The SOC with the BCM related ADE which most South Korean geriatrics on BCMs for \>1 day were at risk of was the "composite of multiple SOCs" group (mean proportion = 0.0134). The reason for this was because the third and fourth most common ADEs in this population which were rash/urticaria/pruritus and dizziness/somnolence from diazepam corresponded to multiple adverse events. Excluding the "composite of multiple SOCs" group, this geriatric population was most at risk of ADEs in the "cardiac disorders" SOC (mean proportion = 0.0082). This was followed by the "gastrointestinal disorders" SOC (mean proportion = 0.0064) and "general disorders and administration site conditions" SOC (mean proportion = 0.0059). The SOC with the BCM related ADE which most South Korean geriatrics on BCMs for ≤1 day were at risk of was the "composite of multiple SOCs" group (mean proportion = 0.0032). The reason for this was because the first and second most common ADE in this population which were rash/urticaria/pruritus from diazepam and dizziness/somnolence from lorazepam corresponded to multiple adverse events. Excluding the "composite of multiple SOCs" group, this population was most at risk of ADEs in the "cardiac disorders" SOC (mean proportion = 0.0018) followed by the "vascular disorders" SOC (mean proportion = 0.0011) and "gastrointestinal disorders" SOC (mean proportion = 0.0006).

The SOC with the BCM related ADE which most US geriatrics were at risk of was "psychiatric disorders" (mean proportion = 0.0013). This was because the most common ADE in US geriatrics, cyclobenzaprine related somnolence, corresponded to the SOC "psychiatric disorders". This was followed by the "composite of multiple SOCs" (mean proportion = 0.0011) and the "gastrointestinal disorders" SOC (mean proportion = 0.0010) and. The SOC including the most BCM-ADE pairs was "nervous system disorders" for both South Koreans on BCMs for more than 1 day and US geriatric cases at 18 pairs and 33 pairs, respectively.

Using the 16 SOCs where South Koreans had ADE rates available, the proportion of South Korean geriatrics prescribed a BCM \>1 day versus ≤1 day were compared. The mean overall proportion of South Korean geriatrics on BCMs \>1 day at risk of experiencing an ADE of 0.005 was significantly higher than that of South Korean geriatrics on BCMs ≤1 day of 0.001 (2-way ANOVA post hoc pairwise *t*-test, *P* = 0.001). Although not significant, South Korean geriatrics on BCMs \>1 day were shown to have a higher mean risk of ADEs grouped into 10 SOCs "cardiac disorders", gastrointestinal disorders", "general disorders and administration site conditions", "hepatobiliary disorders", "investigations", "metabolism and nutrition disorders", "nervous system disorders", "psychiatric disorders", "vascular disorders", and "composite of multiple SOCs" than geriatrics on BCMs ≤1 day. There were no SOCs where South Korean geriatrics on BCMs ≤1 day had a higher mean risk of ADEs than geriatrics on BCMs \>1 day. There were no SOCs where South Korean geriatrics on BCMs for 1 day or less were of higher risk than South Korean geriatrics on BCMs \>1 day. Comparing the mean risk of SOC-grouped ADEs between SOCs, the mean risk of ADEs grouped into the "composite of multiple SOCs" group was significantly higher than the ADEs grouped into the SOCs "investigations", "nervous system disorders", and "skin and subcutaneous tissue disorders" respectively in the South Korean geriatrics on BCMs.

Using the 15 SOCs where both South Korean and US populations had ADE rates available, the proportion of South Korean and US geriatrics at risk of SOC-grouped ADEs from BCMs were also compared. The mean proportion of geriatrics at risk of experiencing the ADEs was significantly higher in South Korean geriatrics on BCMs \>1 day at 0.005 compared to US geriatrics at 0.001 (2-way ANOVA post hoc pairwise *t*-test *P*\<0.0001). Although not significant, for 8 out of the 15 SOCs where ADEs were grouped into ("cardiac disorders", "gastrointestinal disorders", "general disorders and administration site conditions ", "metabolism and nutrition disorders", "nervous system disorders", "psychiatric disorders", "vascular disorders", "composite of multiple SOCs"), South Korean geriatrics on BCMs \>1 day were shown to have a higher mean risk of ADEs than the US geriatrics while the US geriatric population had a higher mean risk of ADEs than the South Korean geriatric population for 7 SOCs which were "eye disorders", "injury, poisoning and procedural complications", "investigations", "musculoskeletal and connective tissue disorders", "renal and urinary disorders", "reproductive system and breast disorders", and "skin and subcutaneous tissue disorders". Finally, the mean risk of ADEs grouped into the "composite of multiple SOCs" group was significantly higher than the ADEs grouped into the SOCs "cardiac disorders", "gastrointestinal disorders", "general disorders and administration site conditions", "injury, poisoning and procedural complications", "investigations", "metabolism and nutrition disorders", "nervous system disorders", "psychiatric disorders", "renal and urinary disorders", "skin and subcutaneous tissue disorders", and "vascular disorders" respectively in the South Korean geriatrics on BCMs \>1 day and US geriatric populations combined.

Discussion {#sec018}
==========

This study discovered that the exposure of South Korean geriatrics to BCMs was prevalent in that over half of this population was exposed to these medications and the proportion of the population at risk of the ADEs from BCMs was around three-fold higher in South Korean geriatrics (limited to those prescribed BCMs \>1 day) compared to US geriatrics. BCM classes that were most prevalently prescribed in South Korean geriatrics in year 2011 regardless of duration of BCM prescription were first generation antihistamines and benzodiazepines. Specific medications of the first generation antihistamines were chlorpheniramine, dimenhydrinate, and hydroxyzine. These medications have risk of ADEs such as dizziness or drowsiness and this may be debilitating in the elderly as the ADEs may lead to falls or fractures. The benzodiazepines were diazepam and alprazolam and use of these medications in geriatrics increases their risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes. The high prescribing rate of these medications in South Korean geriatrics is concerning and this warrants heightened awareness in prescribers regarding the risk of ADEs from BCMs. This issue is becoming more important due to the increased lifespan of the population and use of multiple medications in the geriatric population.

Notable differences in BCM exposure patterns between South Korean geriatrics prescribed chronic (in present study \>1 day) and short duration (in present study, 1 day or less) BCMs were that ketorolac and atropine were prescribed more frequently in a short duration of 1 day or less instead of chronically. This may be due to ketorolac being indicated for short term pain or surgical procedures and atropine is indicated acutely for cardiac arrest or organophosphate poisoning \[[@pone.0191376.ref074]\]. Although other than atropine and ketorolac, the absolute number of South Korean geriatrics prescribed BCMs short term were smaller than geriatrics prescribed BCMs longer term, the relative prescribing trend of the latter BCMs were similar in both populations. The trend of BCM prescribing between South Korea and the US was also similar. The most prevalently prescribed meds for US geriatrics in 2014 were benzodiazepines including alprazolam, lorazepam, zolpidem, and clonazepam. Alprazolam was one of the most commonly prescribed medications in both South Korea and the US.

In South Korean geriatrics prescribed BCMs for \>1 day, the ADE rates from amitriptyline were among the highest out of all BCM ADEs examined in this study. Specifically, dry mouth from amitriptyline was the ADE with the highest number of geriatrics at risk of experiencing. Sleepiness, dizziness, and constipation related to amitriptyline were other ADEs that many South Korean geriatrics were at risk of. The reasons for this trend was because the number of patients on amitriptyline and the incidence of ADEs from this drug were high. Diazepam related rash/urticaria/pruritus was the 3^rd^ most common ADE predicted to occur in South Korean geriatrics after amitriptyline ADEs and this also reflects the high number of geriatrics on diazepam. Thus, monitoring geriatrics for anticholinergic changes or toxicities after prescribing medications is important and necessary. The SOCs of ADEs that most of this South Korean population was at risk of were "cardiac disorders" (mean proportion = 0.0082), "gastrointestinal disorders" (mean proportion = 0.0064), and "general disorders and administration site conditions" (mean proportion = 0.0059), after excluding "composite of multiple SOCs" (mean proportion = 0.0134). This shows that monitoring geriatrics for their change in cardiac system or gastrointestinal condition for the possibility of ADEs from medications and adjusting their drug treatment accordingly may improve the safety of drug therapy in geriatrics.

Similarly, for geriatrics of South Korea prescribed BCMs for 1 day or less, ADEs from the benzodiazepines diazepam and lorazepam including rash/urticarial/pruritus, dizziness/somnolence, and dyspnea were those that most of these geriatrics were at risk of. Dry mouth from amitriptyline was also one of the high risk ADEs in this population. Therefore, monitoring geriatrics for their neuropsychiatric, cardiac, and anticholinergic symptoms after medication use and prevention of these ADEs is necessary. Considering that ADEs of the SOC "cardiac disorders" was the most prevalent ADEs this population was at risk of (mean proportion of population at risk = 0.0018) excluding the "composite of multiple SOCs" group, care to avoid medications with cardiotoxicity in this population may be needed.

Examining ADEs predicted in US geriatrics, the trend of ADEs that geriatrics were at risk of were not similar to those in South Korean geriatrics. The ADE that the highest number of US geriatrics was at risk of having was somnolence from cyclobenzaprine. The other ADEs that many US geriatrics were at risk of experiencing were dry mouth, headache, dizziness, and blurred vision from cyclobenzaprine, restlessness from lorazepam, and dizziness/blurring of vision/dry mouth from dicyclomine, and fatigue and dyspnea from atropine (excluding ophthalmic). The most common SOCs of ADEs that US geriatrics were at risk of were "psychiatric disorders" (mean proportion = 0.0013), "gastrointestinal disorders" (mean proportion = 0.0010), and "nervous system disorders" (mean proportion = 0.0009), after excluding "composite of multiple SOCs" (mean proportion = 0.0011).

Comparing the mean proportion of patients at risk of ADEs in 15 SOC groups, South Korean geriatrics on BCMs \>1 day were at a higher risk of ADEs in 7 single SOCs plus the "composite of multiple SOCs" group than US geriatrics, although not statistically significant. The 7 single SOCs were "cardiac disorders", "gastrointestinal disorders", "general disorders and administration site conditions", "metabolism and nutrition disorders", "nervous system disorders", "psychiatric disorders", and "vascular disorders". However, the proportion of geriatrics at risk of the 15 SOC-grouped ADEs combined was statistically significantly higher in South Korea than in the US, showing that medication prescribing for geriatrics in South Korea may require modification or further monitoring regarding its safety outcomes. Although not statistically significant, US geriatrics were at a higher risk of experiencing ADEs in the SOCs "eye disorders", "injury, poisoning and procedural complications", "investigations", "musculoskeletal disorders", "renal and urinary disorders", "reproductive system and breast disorders", and "skin and subcutaneous tissue disorders" than South Korean geriatrics on BCMs \>1 day.

This study was the first to systematically examine the exposure of all BCMs in South Korean and US geriatrics and the risk of ADEs from these medications. This analysis enabled a comprehensive overview of the extent of geriatric risk of ADEs using population data. These results may be generalizable to the total national population as the South Korean HIRA national patient sample dataset was shown to represent the total South Korean population \[[@pone.0191376.ref009]\] and the US Medicare Part D data includes prescription information of American geriatrics 65 years or older \[[@pone.0191376.ref075]\]. Therefore, the results of this study may be used as a reference to evaluate the current drug therapy in geriatrics.

As this study was cross sectional, there were some limitations. Firstly, the results of this study present medication exposure and ADE risk data for a one-year range providing only a snapshot of BCM exposure and ADE risk. Data of a longer period would enable examination of the change in med exposure or ADE risk over time providing stronger evidence for risk of ADEs from BCMs and enable the inclusion of additional BCMs. The latter is due to the fact that some BCMs were permitted to be used as an alternate to a med used for a certain indication. In this study, as the medication history of a patient was infeasible to determine over a year, we excluded BCMs that were to be avoided under particular medication use or disease histories. Secondly, it was not possible to determine if the patients actually took the drugs as this study used claims data. Thirdly, follow up of patients' clinical status was not possible. Confirming if the patients on BCMs had an ADE with the claims data would provide direct evidence of ADE risk from the med. However, whether the patients exposed to BCMs experienced ADEs is unknown with our study as the patients in the study data were anonymized and linking the claims data of patients in this study to other data was not possible. Lastly, considering that approximately 0.2% of the South Korean geriatric population are using hospice care, our study may have overestimated the exposure of geriatrics exposed to BCMs as this criteria applies to geriatrics not receiving hospice or palliative care. This population could not be excluded from this study sample because information on whether the geriatric was having this type of care was not discernable from our study data. However, this overestimation did not alter the trend or direction of the study results.

Conclusions {#sec019}
===========

To conclude, this study found that there is room for improvement in South Korean geriatric drug therapy through enhanced awareness and education of clinicians regarding medications that may be potentially inappropriate for geriatrics. This was known from the fact that at least half of South Korean geriatrics were exposed to medications recommended to be avoided in geriatrics according to the Beers Criteria and a significantly higher proportion of South Korean geriatrics on BCMs \>1 day were at risk of ADEs from the BCMs compared to US geriatrics. Heightened awareness from clinicians regarding safe geriatric drug therapy may contribute to increased quality of drug treatment in South Korean geriatrics.
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